Showing results (81-90 of 237) with videos related to
Sort By:
Pageof 24
Current Medical Research and Opinion|January 26, 2008
Lipid abnormalities and cardiovascular risk in the elderlyHaralampos J Milionis, Moses S Elisaf, Dimitri P MikhailidisCurrent Pharmaceutical Design|January 3, 2013
Pioglitazone and cancer: angel or demon?Michael S Kostapanos, Moses S Elisaf, Dimitri P MikhailidisExpert Opinion on Drug Metabolism & Toxicology|April 22, 2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]Theodosios D Filippatos, Vasilios G Athyros, Moses S ElisafJournal of Cardiovascular Pharmacology and Therapeutics|May 8, 2008
An overview of the extra-lipid effects of rosuvastatinMichael S Kostapanos, Haralampos J Milionis, Moses S ElisafAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 29, 2010
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemiaMichael S Kostapanos, Haralampos J Milionis, Moses S ElisafCurrent Vascular Pharmacology|January 14, 2012
Aliskiren in patients with diabetes: a systematic reviewEvangelos C Rizos, Aris P Agouridis, Moses S ElisafKardiologia Polska|November 8, 2023
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitionersPanagiotis Anagnostis, Christina Antza, Matilda Florentin, et al.World Journal of Diabetes|February 25, 2022
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatmentMatilda Florentin, Michael S Kostapanos, Athanasia K PapazafiropoulouJournal of Clinical Medicine|November 24, 2020
Hyponatremia in Patients with Hematologic DiseasesEpameinondas Koumpis, Matilda Florentin, Eleftheria Hatzimichael, et al.Clinical Pharmacology : Advances and Applications|October 2, 2019
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetesIoanna Papakitsou, George Vougiouklakis, Moses S Elisaf, et al.Pageof 24